Genetic Technologies Limited (GENE)

Market Cap	3.78M
Revenue (ttm)	6.45M
Net Income (ttm)	-8.02M
Shares Out	145.42M
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,539
Open	0.790
Previous Close	0.765
Day's Range	0.765 - 0.790
52-Week Range	0.670 - 3.750
Beta	0.48
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 22, 2024

About GENE

Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people’s health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. The company also markets BREVAGenplus to healthcare professionals in breast health c...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1989
• Employees: 55
• Stock Exchange: NASDAQ
• Ticker Symbol: GENE
• Website: https://genetype.com

Financial Performance

In 2024, Genetic Technologies's revenue was 9.67 million, a decrease of -6.52% compared to the previous year's 10.35 million. Losses were -12.02 million, 2.27% more than in 2023.

Financial numbers in AUD